Revisiting the Role of Insulin-Like Growth Factor-I Receptor Stimulating Activity and the Apolipoprotein E in Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Background: Alterations in Insulin-Like Growth Factor I (IGF-I) signaling have been associated with dementia and Alzheimer’s disease. Studies on the association between IGF-I levels and dementia risk have been inconclusive. We reported earlier that higher levels of IGF-I receptor stimulating activity are associated with a higher prevalence and incidence of dementia. Objective: In the present study, we test the robustness of the association between IGF-I receptor stimulating activity and dementia by extending the follow-up period to 16 years and investigate possible effect modification by apolipoprotein E. Methods: At baseline, circulating IGF-I receptor stimulating activity was determined by the IGF-I KIRA assay in 1,014 elderly from the Rotterdam Study. Dementia was assessed from baseline (1997-1999) to follow-up in January 2015. Associations of IGF-I receptor stimulating activity and incident dementia were assessed with Cox proportional hazards models. Results: During 10,752 person-years of follow-up, 174 people developed dementia. In the extended follow-up we no longer observed a dose-response relationship between IGF-I receptor stimulating activity and risk of dementia (adjusted odds ratio 1.11; 95% CI 0.97-1.28). Interestingly, we found evidence of an interaction between ApoE-4 and tertiles of IGF-I receptor stimulating activity. IGF-I receptor stimulating activity in the median and top tertiles was related to increased dementia incidence in hetero- and homozygotes of the ApoE-4 allele, but did not show any association with dementia risk in people without the ApoE-4 allele (adjusted odds ratio medium versus low IGF-I receptor stimulating activity in ApoE-4 carriers: 1.45; 95% CI 1.00-2.12). These findings suggest a threshold effect in ApoE-4 carriers. In line with the hypothesis that downregulation of IGF-I signaling is associated with increased dementia risk, ApoE-4 homozygotes without prevalent dementia displayed lower levels of IGF-I receptor stimulating activity than heterozygotes and non-carriers. Conclusion: The findings shed new light on the association between IGF-I signaling and the neuropathology of dementia and ask for replication in other cohorts, using measures of IGF-I receptor stimulating activity rather than total serum levels as putative markers of dementia risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Self-citationTalbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871 · cited 2×
“…IGF-I is an important mediator in the clearance and regulation of Aβ in the brain, enhances survival of neurons exposed to Aβ and inhibits tau phosphorylation (Doré et al., 1997; Carro et al., 2002, 2006; Cheng et al., 2005; Engel et al., 2006; Moloney et al., 2010; Talbot et al., 2012).”
BackgroundSteen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703 · cited 1×
“, 2010) with alterations in both the levels and phosphorylation state of IGF-I receptor (IGF-IR) as well as the levels and distribution of IGF-I and IGF-IR mRNA in the brain (Rivera et al., 2005; Steen et al., 2005).”
BackgroundAPOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging
Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., & Mintun, M. A. (2010) · Annals of Neurology · doi:10.1002/ana.21843 · Cited by 830
Reiman, E. M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., Ayutyanont, N., Keppler, J., Reeder, S. A., Langbaum, J. B. S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900345106 · Cited by 785 · cited 1×
“The NR2B subunit of the NMDA receptor, in particular, is suggested to be of specific importance for spatial learning and long-term potentiation, impaired in AD (Sonntag et al., 2000; Le Grevès et al., 2005; Reiman et al., 2009).”
BackgroundMoloney, A. M., Griffin, R. J., Timmons, S., O’Connor, R., Ravid, R., & O’Neill, C. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.04.002 · Cited by 764 · cited 8×
“IGF-I signaling is also markedly disturbed in the brain of patients with Alzheimer’s Disease (AD; Frölich et al., 1998, 1999; Moloney et al., 2010) with alterations in both the levels and phosphorylation state of IGF-I receptor (IGF-IR) as well as the levels and distribution of IGF-I and IGF-IR mRNA in the brain (Rive…”
BackgroundInfluentialBrain insulin and insulin receptors in aging and sporadic Alzheimer’s disease
Frölich, L., Blum-Degen, D., Bernstein, H.-G., Engelsberger, S., Humrich, J., Laufer, S., Muschner, D., Thalheimer, A., Türk, A., Hoyer, S., et al. (1998) · Journal of Neural Transmission · doi:10.1007/s007020050068 · Cited by 748
Rivera, E. J., Goldin, A., Fulmer, N., Tavares, R., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-8304 · Cited by 723 · cited 1×
“, 2010) with alterations in both the levels and phosphorylation state of IGF-I receptor (IGF-IR) as well as the levels and distribution of IGF-I and IGF-IR mRNA in the brain (Rivera et al., 2005; Steen et al., 2005).”
BackgroundFunctionally significant insulin-like growth factor I receptor mutations in centenarians
Suh, Y., Atzmon, G., Cho, M.-O., Hwang, D., Liu, B., Leahy, D. J., Barzilai, N., & Cohen, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705467105 · Cited by 703 · cited 1×
“Suppression of IGF-I signaling has been associated with longevity in humans (Suh et al., 2008) and has shown to delay the process of aging and increase lifespan in model organisms (Tatar et al.”
BackgroundApoE and Aβ in Alzheimer’s Disease: Accidental Encounters or Partners?
Kanekiyo, T., Xu, H., & Bu, G. (2014) · Neuron · doi:10.1016/j.neuron.2014.01.045 · Cited by 608 · cited 1×
“The ApoE-ε4 allele, on the other hand, is associated with decreased Aβ1–42 and higher tau and p-tau in the CSF and increased cerebral amyloid deposition across the AD spectrum (Tapiola et al., 2000; Morris et al., 2010; Leoni, 2011; Risacher and Saykin, 2013; Wildsmith et al., 2013; Kanekiyo et al., 2014).”
Cited by
Amyloid-β oligomers in cellular models of Alzheimer’s disease
Fontana, I. C., Zimmer, A. R., Rocha, A. S., Gosmann, G., Souza, D. O., Lourenco, M. V., Ferreira, S. T., & Zimmer, E. R. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15030 · Cited by 115
“Nevertheless, in humans low IGF-1 activity is linked to increased risk of dementia, mainly in subjects harboring the ApoE4 genotype (Galle et al., 2019).”
Brain high-throughput multi-omics data reveal molecular heterogeneity in Alzheimer’s disease
Eteleeb, A. M., Novotny, B. C., Tarraga, C. S., Sohn, C., Dhungel, E., Brase, L., Nallapu, A., Buss, J., Farias, F., Bergmann, K., et al. (2024) · PLOS Biology · doi:10.1371/journal.pbio.3002607 · Cited by 64
Agrawal, M., Perumal, Y., Bansal, S., Arora, S., & Chopra, K. (2020) · Food and Chemical Toxicology · doi:10.1016/j.fct.2020.111684 · Cited by 54
Circulating IGFBP‐2: a novel biomarker for incident dementia
McGrath, E. R., Himali, J. J., Levy, D., Conner, S. C., DeCarli, C. S., Pase, M. P., Courchesne, P., Satizabal, C. L., Vasan, R. S., Beiser, A. S., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50854 · Cited by 49
Impact of Genetic Risk Factors for Alzheimer’s Disease on Brain Glucose Metabolism
Cho, S., Lee, H., & Seo, J. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02297-x · Cited by 25
Metadata
- Authors
- Galle, S. A., van der Spek, A., Drent, M. L., Brugts, M. P., Scherder, E. J. A., Janssen, J. A. M. J. L., Ikram, M. A., & van Duijn, C. M.
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2019-02-12
- Volume
- 11
- Pages
- 20-20
- ISSN
- 1663-4365 (ISSN-L)
- OpenAlex
- W2913638709
- Cited by
- 31
- References
- 12
- FWCI
- 3.34
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Revisiting the Role of Insulin-Like Growth Factor-I Receptor Stimulating Activity and the Apolipoprotein E in Alzheimer’s Disease. https://app.cochat.ai/papers/10.3389/fnagi.2019.00020
- The paper
- Galle, S. A., van der Spek, A., Drent, M. L., Brugts, M. P., Scherder, E. J. A., Janssen, J. A. M. J. L., Ikram, M. A., & van Duijn, C. M. (2019). Revisiting the Role of Insulin-Like Growth Factor-I Receptor Stimulating Activity and the Apolipoprotein E in Alzheimer’s Disease. Frontiers in Aging Neuroscience. https://doi.org/10.3389/fnagi.2019.00020
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.